Facebook
Twitter
LinkedIn
Forward
Unmasking Neurotrophic Keratitis: Diagnosing and Treating All Stages (Archived CE Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Neurotrophic keratitis (NK) is a degenerative corneal condition due to decreased or absent sensory corneal innervation. Early diagnosis can be challenging. Optimal treatment of all stages of NK is crucial for restoring epithelial integrity, mitigating progression of corneal damage, and preventing recurrent defects. This case-based educational activity can help “unmask” potential best practices in the diagnosis and treatment of all stages of NK.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate evaluation of corneal sensitivity into routine assessment of ocular surface disease
- Select treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
Faculty
 | Lisa M. Nijm, MD, JD (Chair) Assistant Professor of Ophthalmology University of Illinois Eye and Ear Infirmary Chicago, Illinois Founder and Medical Director Warrenville EyeCare and LASIK Center Warrenville, Illinois |
 | W. Barry Lee, MD, FACS |
 | Leslie E. O’Dell, OD, FAAO |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
W. Barry Lee, MD, has no relevant commercial relationships to disclose.
Lisa M. Nijm, MD, JD, is a consultant for Alcon, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TruKera Medical, Thea Pharmaceuticals Limited, and Visus Therapeutics; is an advisory board member of Alcon, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, and Trukera Medical; is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Horizon Therapeutics plc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Ocular Therapeutix, Inc; and has stock options in TruKera Medical that have not been exercised.
Leslie E. O’Dell, OD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Eye Eco Inc, Eyedetec Medical, Inc, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Allergan, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and has stock options that have not been exercised in Èssiri Labs and Eyedetec Medical, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 85808-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 126567, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this COPE-Accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Dompé US, Inc.
©2023 MedEdicus LLC. 298.2